Home Page News Opinion Foreign Policy Politics Policy Legislation Lobbying Hill Life & People Hill Climbers Heard On The Hill Calendar Archives Classifieds
Hill Times Events Inside Ottawa Directory Hill Times Books Hill Times Careers The Wire Report The Lobby Monitor Parliament Now
Subscribe Free Trial Reuse & Permissions Advertising
Log In
Policy Briefing: Biotechnology

Innovation lagging, but feds promise comprehensive review of R&D support, says Clement

Industry Minister Tony Clement says his top priority as the minister responsible for the biotechnology portfolio is to keep the industry and business climate competitive.
The biotech industry's national association, BIOTECanada, spent last Tuesday in 50 meetings with federal politicians and senior government officials lobbying them to kill C-474, among other issues.
Without access to capital in Canada, companies will go elsewhere to commercialize the results of research funded by Canadian tax dollars, say biotech industry players.
Africa needs more global science partnerships and a new generation of scientists trained to solve the continent's pressing problem of sustainable development.
Biotechnology has emerged as a key sector in the Canadian economy. But there are challenges. Canada has to attract capital funding.
Canada does not have a program to entice pharmaceutical companies to develop and market drugs for rare disorders here. So companies are going elsewhere.

Your group subscription includes premium access to Politics This Morning briefing.